Status:
COMPLETED
COVID-19 Infection in Patients Receiving Anti-CD20 Therapy
Lead Sponsor:
Mayo Clinic
Conditions:
COVID-19
Immunosuppressed Host
Eligibility:
All Genders
18+ years
Brief Summary
This study is being conducted to determine if patients with compromised B-cell function due to anti-CD20 therapy and newly diagnosed COVID-19 infection benefit from convalescent plasma.
Detailed Description
This is a retrospective cohort study comparing patients, with newly diagnosed COVID-19 infection, previously treated with anti-CD20 drugs for diseases including vasculitis or hematologic malignancy, w...
Eligibility Criteria
Inclusion
- Diagnosis of COVID-19 infection
- Positive SARS CoV2 PCR
- Enrolled in the Mayo Clinic COVID-19 registry
- History of treatment with anti-CD20 drugs within past 3 years
Exclusion
- Patients who declined to have their chart reviewed for research purpose.
- Patients who have received convalescent plasma within the previous 3 months of COVID-19 diagnosis
- Patients who have received monoclonal antibodies that target SARS-CoV-2 in the past three months
Key Trial Info
Start Date :
June 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 15 2023
Estimated Enrollment :
342 Patients enrolled
Trial Details
Trial ID
NCT04884477
Start Date
June 1 2021
End Date
January 15 2023
Last Update
March 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905